Pharmacological Management of Breakthrough Cancer Pain: Current Strategies

Breakthrough cancer pain (BTcP) is a sudden, transient exacerbation of pain that occurs despite otherwise stable and adequately controlled baseline pain. It significantly impacts the quality of life in cancer patients and presents unique therapeutic challenges. This review explores current pharmacological strategies for the effective management of BTcP, focusing on rapid-onset opioids (ROOs), including transmucosal fentanyl formulations, their pharmacokinetics, dosing considerations, and safety profiles. Emphasis is placed on individualizing treatment based on patient-specific factors such as opioid tolerance, cognitive status, and route of administration. The review also discusses the limitations of conventional opioids like morphine in managing BTcP due to slower onset. Furthermore, the article highlights the importance of ongoing patient assessment, titration protocols, and the integration of pharmacological therapy into a broader, multidisciplinary pain management approach. Optimizing BTcP treatment remains a dynamic process requiring clinical vigilance, patient education, and access to diverse analgesic options.